2,8-Diacyl-2,8-diazaspiro[5.5]undecane Compounds for PD-1/PD-L1 Blockade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer and infectious diseases, such as HIV and Hepatitis, face challenges due to T cell exhaustion caused by chronic antigen stimulation, where PD-1/PD-L1 interactions inhibit immune responses, leading to reduced efficacy of existing therapies.
Innovation Solution
Development of compounds that inhibit the PD-1/PD-L1 and CD80/PD-L1 protein interactions, enhancing immune responses by blocking these inhibitory pathways, thereby restoring T cell function and immune activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PD-1/PD-L1 interactions are allowed to occur, then immune responses are suppressed during chronic infection or tumor, but T cell function is lost leading to reduced therapy efficacy
Solution Approach 1:
The patent uses small molecule compounds as intermediaries that bind to PD-L1 and prevent its interaction with PD-1 on T cells. These compounds act as mediators that block the inhibitory signal transmission, allowing T cells to maintain their function despite the presence of PD-L1 expressing tumor cells or infected cells.
Solution Approach 2:
The patent modifies the binding parameters of the PD-1/PD-L1 interaction by introducing compounds that change the affinity and specificity of the interaction. The compounds alter the biochemical parameters of the protein-protein interaction, preventing the formation of the inhibitory complex and restoring T cell activation.
2Reliability
If monoclonal antibodies are used to block PD-1/PD-L1, then T cell activation is restored, but treatment cost and complexity increase
Solution Approach 1:
The patent replaces expensive monoclonal antibodies with smaller, more affordable small molecule compounds. These small molecules are easier to produce, more cost-effective, and can be administered through oral or intravenous formulations that are simpler to implement clinically compared to intravenous monoclonal antibody infusions.
Solution Approach 2:
The patent substitutes the biological mechanism of monoclonal antibodies (protein-based immune response modulation) with a chemical mechanism (small molecule binding to PD-L1). This substitution simplifies the therapeutic approach by using direct molecular binding rather than complex protein-protein interactions, reducing both manufacturing complexity and clinical administration requirements.
3Productivity
If PD-L1 blockade is used to treat cancer, then immune response is enhanced, but off-target effects and toxicity may occur
Solution Approach 1:
The patent achieves local specificity by designing compounds that selectively bind to PD-L1 expressed on tumor cells and infected cells while sparing normal tissues. The molecular structure of the compounds is optimized to recognize specific epitopes on PD-L1, ensuring that the blocking effect is localized to the pathogenic PD-1/PD-L1 interactions rather than affecting all PD-L1 expressions throughout the body.
Solution Approach 2:
The patent employs partial blocking at optimal concentrations, where the small molecules bind to PD-L1 with high affinity but do not completely eliminate all PD-L1 function. This partial action approach allows sufficient blocking of the inhibitory pathway to restore T cell function while avoiding excessive blockade that could lead to autoimmune reactions or off-target effects.
Data Source
AI summary
The present disclosure generally relates to compounds of formula (I) useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.